The American Gastroenterological Association (AGA) today announced the launch of My IBD Manager, a new digital patient resource developed for the 1.6 million Americans living with Crohn’s disease and ulcerative colitis, collectively known as inflammatory bowel disease (IBD), and the doctors who treat them. This will be followed by the launch of an online clinical platform for health care professionals, ...

Clinical trial recruitment is a challenging step toward FDA approval of new treatments for patients across all disease states; this is especially true for inflammatory bowel diseases (IBD). The Crohn’s & Colitis Foundation (the Foundation) launched today a dedicated Clinical Trials Community (the Community) for IBD. The Community is designed to educate patients, caregivers, and healthcare providers about the clinical ...

Clinical trial recruitment is a challenging step toward FDA approval of new treatments for patients across all disease states; this is especially true for inflammatory bowel diseases (IBD). The Crohn’s & Colitis Foundation (the Foundation) launched today a dedicated Clinical Trials Community (the Community) for IBD. The Community is designed to educate patients, caregivers, and healthcare providers about the clinical ...

Improperly cleaned medical equipment at the clinic at Al Udeid Air Base in Qatar may have exposed as many as 135 patients to blood-borne diseases such as HIV and Hepatitis B and C over an eight-year period. The Air Force Surgeon General said Monday that Air Force Medical Service found that endoscopes used for upper and lower gastrointestinal procedures “were ...

Tillotts Pharma is strengthening its presence in the German market: the Berlin office was opened in January 2017 under the management of Magdalena Kritikos. The portfolio includes Entocort® for the treatment of Crohn’s disease, Asacol® for the treatment of ulcerative colitis, and VistaPrep® for bowel preparation before endoscopy. With further innovative solutions, the Swiss specialty pharmaceutical company focused on the treatment of gastrointestinal (GI) diseases will expand its global footprint with its growing presence in Germany and will continue to work to improve the quality ...